Phase I Trial of Fenretinide Delivered Orally in a Novel Organized Lipid Complex in Patients with Relapsed/Refractory Neuroblastoma: A Report from the New Approaches to Neuroblastoma Therapy (NANT) Consortium

BACKGROUND: A phase I study was conducted to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics of fenretinide (4-HPR) delivered in an oral powderized lipid complex (LXS) in patients with relapsed/refractory neuroblastoma. PROCEDURE: 4-HPR/LXS powder (352 - 2...

Full description

Saved in:
Bibliographic Details
Main Authors: Maurer, Barry J., Kang, Min H., Janeba, Jitka, Villablanca, Judith G., Groshen, Susan, Matthay, Katherine K., Sondel, Paul M., Maris, John M., Jackson, Hollie A., Goodarzian, Fariba, Shimada, Hiroyuki, Czarnecki, Scarlett, Hasenauer, Beth, Reynolds, C. Patrick, Marachelian, Araz
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4066886/
https://ncbi.nlm.nih.gov/pubmed/23813912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24643
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items